#USA #New York #Nuvation Bio #safusidenib #IDH1-Mutant

Nuvation Bio's Strategic Expansion of the SIGMA Study

Nuvation Bio Inc., a global leader in oncology, has recently declared its significant strategic move to broaden the pivotal Phase 3 SIGMA study of
safusidenib, a treatment for IDH1-mutant glioma, by adding six new European countries to its list of research sites. This expansion marks a notable step in the quest for innovative cancer therapies and enhances the project's global reach.

The newly chosen sites will be located in the UK, France, Sweden, Germany, Italy, and Spain, thus complementing the already active sites in the USA, Australia, China, Canada, and Japan, where the study has commenced patient enrollment or is set to do so shortly.

Dr. David Hung, the founder and CEO of Nuvation Bio, emphasized the company’s commitment to creating impactful therapies for patients dealing with challenging cancers. He stated, “Our goal is to develop therapies that create a profound, positive impact on patients' lives. Expanding SIGMA to sites across six European countries is an important step for patients, and we have been encouraged by the strong interest from physicians and the glioma community in Europe.” This sentiment reflects a larger movement within the oncology sector to diversify patient enrollment in clinical studies, aiming for broader demographics and more comprehensive data collection.

The SIGMA study, identified by the ClinicalTrials.gov number NCT05303519, is a randomized, placebo-controlled trial aiming to evaluate the efficacy of safusidenib as a maintenance therapy following standard treatment methods, such as radiotherapy and chemoradiotherapy, in patients suffering from IDH1-mutant astrocytoma demonstrating high-risk features. The primary goal of the study is to analyze progression-free survival, a critical measurement of treatment effectiveness in oncology.

Approximately 300 patients are expected to be enrolled in the pivotal segment, with a secondary exploratory cohort planned to assess safusidenib's effect on around 40 chemotherapy- and radiotherapy-naïve patients with grade 3 IDH1-mutant oligodendroglioma. This vast reach not only shows Nuvation Bio's ambition but also the pressing need for innovative treatments in an area of significant unmet medical need.

IDH1-mutant gliomas are among the most prevalent forms of brain cancer in adults globally, with around 2,500 new cases diagnosed annually in the US alone. With over 95% of these cases possessing a mutation in the IDH1 gene, treatment options remain limited, and there is a notable gap for patients with high-grade tumors, which typically present a grim prognosis. Thus, therapies like safusidenib hold promise for altering outcomes in this patient population.

Safusidenib is an oral brain-penetrant selective inhibitor designed to target mutant IDH1. In previous Phase 1 and 2 trials, it showcased encouraging clinical activity, indicating delays in disease progression and durable responses across various tumor grades. These findings bolster the rationale for the ongoing progression of the Phase 3 SIGMA study, further aiming to support healthcare professionals in their efforts against glioma.

In August 2026, the FDA granted Fast Track Designation for safusidenib, validating its potential as a viable treatment for patients with IDH1-mutant glioma. This designation highlights the drug's promise in an arena where treatment alternatives are sparse, thus generating hope for both patients and practitioners alike.

As Nuvation Bio continues to navigate the challenges within drug development, including regulatory processes and clinical trial enrollment, the commitment to transparency regarding risks and uncertainties remains clear. The company is determined to forge past obstacles and deliver innovative solutions that can significantly improve patient quality of life.

With the global clinical landscape continually evolving, Nuvation Bio's expansion of the SIGMA study signifies not just a step forward in clinical research but also a profound hope for patients worldwide affected by IDH1-mutant glioma.